Kornimate/medical-research-clean huggingface dataset:
rice technologies for cervical cancer screening and diagnosis

Conditions: Cervical Cancer

Summary: the study aims to compare the accuracy of the lateral flow test to detect hpv at the poc with commercially available hpv test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

this is a prospective, single-arm community trial involving 678 women aged 25 to 49 years for evaluation of positive cervical cancer screening tests (abnormal cytology, via+ and/or hpv+ test). eligible women will be offered enrollment at the time of their consultation for a follow-up of their abnormal cervical cancer screening test. participating centers include: 1) mavalane hospital and health center and 2) josé macamo general hospital (josé macamo), 3) maputo central hospital. after providing the informed consent, the participant will answer a short questionnaire that will include demographic information and medical background, including hiv status (hiv-negative, positive, or unknown, and, among women with hiv-positive tests, hiv viral load and cd4 cell count, if available), and cervical cancer screening test results. the patient will undergo a rapid urine - poc pregnancy test (within 14 days from the date of enrollment). each participant will then receive instructions and will provide two cervico-vaginal samples taken by the patient herself (self-collection). the patient will then undergo a pelvic examination with two cervical samples taken by the healthcare provider. 7. a sample taken by the patient herself (self-collection) and a sample taken by the provider will be sent for an hpv test using genexpert. similarly, samples taken by the patient herself (self-collection) and collected by the provider will be stored for the rice poc rapid hpv test. the patient will then undergo multimodal imaging. images/videos of the cervix will be obtained using the mobile colposcope/smartphone and hrme images/videos will be also obtained.

Eligibility criteria:
inclusion criteria: 1. 25 - 49 year old women 2. women with a positive cervical cancer screening test (abnormal cytology, positive via and/or positive hpv test) 3. women with intact cervix 4. women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding 5. willing and capable of providing informed consent exclusion criteria: 1. women under 25 or over 49 years old 2. women who have undergone a total hysterectomy (with removal of the cervix) 3. women who are pregnant or breastfeeding

Keywords: human papilloma virus point-of-care hpv test multimodal optical imaging screening
validation of quality of life assessment after laparoscopic tapp and tep surgery of inguinal hernias using eurahs of life score and carolinas comfort scale™

Conditions: Primary Unilateral Inguinal Hernias

Summary: a multicenter observational study trial validating quality of life assessment using eurahs quality of life score and carolinas comfort scale™ in patients before and after laparoscopic unilateral inguinal hernia repair. depending on the treating physician patients will receive a tapp or tep repair for their inguinal hernia and a self-gripping mesh will be used for the repair (parietex progrip mesh). primary endpoint will be assessment by the eurahs-qol at 1 year after laparoscopic repair of an unilateral inguinal hernia using the anatomic progrip™ laparoscopic self-fixating mesh. secondary endpoints are assessment of the qol 3 preoperative, 3 weeks and 1 year postoperative, recurrence rate at 12 months, intra-operative and post-operative complications, post-operative hospital stay, operation time and time to place the mesh, vas (visual analog scale) for pain at several control points, vrs (verbal rating score) for pain at 3 weeks and 12 months, pain medication needed.


Eligibility criteria:
inclusion criteria: * written informed consent from the patient or his/her legal representative * primary unilateral inguinal hernia undergoing a preperitoneal laparoscopic repair. exclusion criteria: * no written informed consent * recurrent groin hernia * open hernia repair * bilateral hernias * concomitant repair of another abdominal hernia eg umbilical hernia * hernia repair combined with another surgical procedure * emergency operations, like incarcerated hernias * patients under the age of 18 years and over 80 years * pregnant women * asa score 4 or more * patients unable to perform the qol assessment, because of language barrier or intellectual incapacity
prognosis of vestibular dysfunction in patients with idiopathic sudden sensorineural hearing loss

Conditions: Vestibular Disorder; Sudden Hearing Loss

Summary: idiopathic sudden sensorineural hearing loss (issnhl) refers to idiopathic sensorineural hearing loss of at least 30 db over at least three test frequencies occurring over a 72-hour period. vertigo has been considered a risk factor of poor prognosis in patients with issnhl. however, the clinical outcome and development of vestibular function in these patients have not been reported yet. we'd like to conduct a study on the problem whether these patients resulted in a complete recovery of the peripheral vestibular functions or compensation of the central vestibular system. if the answer is the former one, these cases might be supportive evidence of regeneration of hair cells in vestibular disorders.

this study is designed as a prospective cohort study with only one cohort. enrolment and data collection are performed by trained research staff who are not involved in the care of the patients. the primary measurement is the vestibular function tests including sot, the caloric reflex test, vhit, vemp (cvemp and ovemp). the secondary measurements included pta, dhi, and vas. the sample size was set at 60 patients. the continuous variables were expressed as means ± standard deviation (sd) whereas categorical variables were expressed as frequency and percentage for data description. p \<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * 16 to 70 years old. * diagnosed as issnhl. * present with vertigo. * at least 1 abnormal result in vestibular function tests(sot, vhit, caloric reflex test, and vemp). * the onset of the disease was within 30 days. exclusion criteria: * unwilling to sign informed consent. * the cause of sudden hearing loss has been identified, such as trauma, vasogenic disease, et al. * bilateral hearing loss. * patients with coexisting vestibular disorders, including meniere disease, vestibular neuritis, labyrinthitis, and peripheral vestibular loss et al. * patients not suitable to receiving vestibular function tests, such as those with severe cervical spine disease, cardiovascular disease, or pregnancy et al. * cognitive impairment; * other conditions that the investigator evaluated the patients as not appropriate for this study.

Keywords: idiopathic sudden sensorineural hearing loss vestibular dysfunction
electro-acupuncture for the prevention and treatment of oxaliplatin-induced neurotoxicity in colorectal cancer patients

Conditions: Colorectal Cancer; Oxaliplatin; Electro-acupuncture; Neurotoxicity

Summary: in this study, a 24-week randomized, sham-controlled, single-blind, multicenter clinical trial will be conducted to explore the effect of electroacupuncture for prevention and treatment of both acute and chronic neurotoxicity through both clinical and biological indicators.

this is a prospective, randomized, sham-controlled, double-blinded and multiple center trial on electro-acupuncture for preventing and treating symptoms of chemotherapy-induced neurotoxicity in patients with colorectal cancer. a total of 150 candidates will be recruited in this study four weeks before chemotherapy for best preventive effect. they will be assigned randomly into either the electro-acupuncture or the sham-control group with 1:1 ratio. both groups will receive a total of 24 sessions of interventions (4 weeks before chemotherapy and 8 weeks during chemotherapy, with 2 session per week), and will be followed up regularly for up to 12 weeks after completion of the acupuncture.

Eligibility criteria:
inclusion criteria: * are aged ≥18 years old; * are newly diagnosed with stage ii to iv colorectal cancer; * going to receive adjuvant oxaliplatin-based chemotherapy within 4 weeks; * had not received any acupuncture in the previous 3 months and had a life expectancy ≥ of six months. exclusion criteria: * are not able to comprehend and communicate; * are not able to read chinese; * have prior peripheral neuropathy caused by other diseases including diabetes, stroke, cardiovascular diseases such as arrhythmia, heart failure, myocardial infarction, and patients with cardiac pacemakers; * have a bleeding tendency; * are pregnant or breastfeeding; * have impaired hepatic or renal function; * using any pharmaceutical agents e.g., vitamin b6 and vitamin e, or herbal medication. all the above medication prescribed by physicians or chinese medicine practitioners during the study will be recorded.
effects of matpilates in pain and functionality in elderly woman with osteoarthritis.

Conditions: Osteoarthritis, Knee

Summary: introduction: the osteoarthrosis is incurable, one of the most incapacitating disease around the world and your prevalence is increasing every year. the main consequences of this disease is pain and loss of functionality as a result of biomechanical limitations coming from articular inflammation. among the variability of therapeutic resources, we propose matpilates like a no drug intervention, that probably will contribute for a decrease in the symptoms of this disease. objective: it is hypothesized that matpilates is a method capable of decrease pain and increase functionality in elderly woman with osteoarthrosis. methods: this study is a randomized double blind clinical trial, in which the volunteer need be in between 60 and 69 years old. will be formed of two groups: matpilates group (mg) and control group (cg), and the ideal "n" will be calculated in a pilot study.


Eligibility criteria:
inclusion criteria: * bilateral osteoarthritis * body mass index (bmi) between 25 and 34,9 (who, 2000) * mini mental state examination score, with cutoff score of 18 (illiterate) and 24 (literate) (brucki et al. 2003; lourenço e veras, 2006) * unassisted gait (no wheelchair, no walking stick, no crutches or no walker) * no history of neurologic disease * no other physical activity * never practiced pilates exclusion criteria: * change in habitual drug's program during the study * join in other physical activity during the study * refuse to wear suitable clothing

Keywords: osteoarthrosis exercise movement techniques pilates elderly physiotherapy
comparative effectiveness of targeted therapies in braf positive metastatic melanoma in the us

Conditions: Melanoma

Summary: this study aims to compare real-world effectiveness of braf/mek inhibitors in braf-mutant metastatic melanoma patients in the united states by line of therapy. the flatiron health electronic health record (ehr) data from us cancer clinics will be used for this retrospective database analysis.


Eligibility criteria:
inclusion criteria: * diagnosed with melanoma based on international classification of disease 9th and 10th revisions (icd-9: 172.x; icd-10: c43x, d03x) and ≥2 visits on different days in the flatiron database on or after january 1, 2011. * clinically confirmed diagnosis of melanoma with pathologic stages iii or iv at initial diagnosis or earlier stage disease with a first locoregional or distant recurrence on or after january 1, 2011. * age ≥18 years at the time of advanced melanoma diagnosis. * evidence of ≥1 braf positive test result at any time based on laboratory or genetic analysis results. exclusion criteria: -• patients with prior braf- or mek-inhibitor therapy • patients with ecog performance status ≥ 2 (at the time of randomization for patients from columbus, during the baseline period for patients in flatiron ehr)

Keywords: braf-mutant metastatic melanoma
a study to evaluate shr-1210 in combination with capecitabine + oxaliplatin sequenced by shr-1210 + apatinib as first-line therapy in treatment of advanced gastric cancer

Conditions: Gastric Cancer; GastroEsophageal Cancer

Summary: this is a randomized, open-label, multi-center, phase iii trial to evaluate the efficacy and safety of shr-1210 plus capecitabine and oxaliplatin sequenced by apatinib with or without shr-1210 versus capecitabine and oxaliplatin as first-line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction (gej) adenocarcinoma.


Eligibility criteria:
inclusion criteria: * has histologically- or cytologically-confirmed diagnosis of locally advanced unresectable or mestastatic adenocarcinoma of stomach or the esophagogastric junction (gej) * age ≥ 18 years old, male or female * no previous therapy for advanced/metastatic disease of gc/gej (including her-2 inhibitor). subjects with previous adjuvant/neo-adjuvant therapy completed more than 6 months can be enrolled. * has measurable disease per recist 1.1 * eastern cooperative group (ecog) performance status of 0 to 1 * has adequate organ function * females of childbearing potential (focbp), who are not surgically sterile or postmenopausal, must conduct pregnancy test (serum or urine) within 7 days before enrollment, and must not be pregnant or breast-feeding women. if the result is negative, she must agree to use adequate contraception during the experiment and 3 months after the last administration of the test drugs. and non-sterilized males who are sexually active must agree to use adequate contraception during the experiment and 3 months after the last administration of the test drugs. exclusion criteria: * has known her2-positive status * has known active central nervous system metastatases * has received a live vaccine within 4 weeks prior to the first dose of study treatment * with any acitve autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatititis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. * has received prior therapy with an anti-pd-1, anti-pd-l1, or anti-ctla-4 antibody, or a vegfr inhibitor. * clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, congestive heart failure (new york heart association (nyha) class \> 2), orventricular arrhythmia which need medical intervention. * hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents: systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg.

Keywords: pd-1 shr-1210
automatic classification of colorectal polyps using probe-based endomicroscopy with artificial intelligence

Conditions: Probe-based Confocal Laser Endomicroscopy; Artificial Intelligence; Colorectal Polyps

Summary: probe-based confocal laser endomicroscopy (pcle) is an endoscopic technique that enables real-time histological evaluation of gastrointestinal mucosa during ongoing endoscopy examination. it can predict the classification of colorectal polyps accurately. however this requires much experience, which limits the application of pcle. the investigators designed a computer program using deep neural networks to differentiate hyperplastic from neoplastic polyps automatically in pcle examination.


Eligibility criteria:
inclusion criteria: aged between 18 and 80; agree to give written informed consent. exclusion criteria: patients under conditions unsuitable for performing cle including coagulopathy , impaired renal or hepatic function, pregnancy or breastfeeding, and known allergy to fluorescein sodium; inability to provide informed consent
treatment of postorthodontic white spot lesions

Conditions: White Spot Lesion of Tooth

Summary: dental caries is the destruction of the tooth structure in the presence of organic acids produced by cariogenic bacteria located in the dental biofilm (dowker et al., 1999 and robinson et al., 2000).tooth enamel comprises 90% substituted hydroxyapatite (ca10 (po4)6(oh) 2), which is subjected to consecutive cycles of demineralization and remineralization. this is an interrupted process, with periods of remineralization and demineralization occurring, depending on the state of the oral environment in terms of the prolonged accumulation and retention of bacterial plaque on the enamel surface (aoba, 2004). oral bacteria ferment carbohydrates to produce organic acids which lower the ph and cause the subsurface dissolution of the hydroxyapatite crystals. under normal physiological conditions (ph7), saliva is supersaturated with calcium and phosphate ions which diffuse into the vacancies created during acid-mediated demineralization episodes (dowker et al., 1999 and robinson et al., 2000). the demineralization of enamel (white spot lesions) is a significant problem during and after orthodontic treatment with prevalence 71.1% and various preventive measures have been suggested to minimize the incidence (derks et al., 2004 and al maaitah et al., 2011).

in orthodontic patients, demineralization usually takes place in the form of white or brown spots on the enamel around the brackets and can lead to cavitation (al maaitah et al., 2011). white spot lesions compromise esthetics and can be extremely difficult or even impossible to reverse. natural remineralization through saliva involving a mineral gain in the surface layer of white spot lesions has little improvement on the esthetic and structural properties of the deeper lesions (karlinsey et al., 2009 and cochrane et al., 2010). management of white spot lesion should involve methods of both preventing demineralization and encourage the remineralization of existing lesions. in both of these processes, the efficacy of fluoride is well established. fluoride increases the initial rate of remineralization of early enamel lesions. consequently, it slows down the caries process and arresting the lesion. fluoride varnish provides a protective coat over the tooth which adheres longer to the tooth surface (demito et al., 2004 and ten cate et al., 2008).

Eligibility criteria:
inclusion criteria: 1. age ranging 11-16 years. 2. good general health. 3. exhibiting at least 2 white spot lesion in buccal surface of their teeth. exclusion criteria: 1. chronic use of medication causing dry mouth. 2. oral ulcer, ulcerous gingivitis, acute bronchial asthma. 3. history of allergic reaction to fluoride or other ingredients in varnish. 4. refusal of the patient to participate in the trial. 5. any previous treatment done for white spot lesion.

Keywords: white spot lesion ,fluoride varnish
study of the fine structure and temporal envelope of the human cochlea in response to human vocalizations

Conditions: Structure Cochlea; Temporal Envelope Cochlea

Summary: in humans, surface electrophysiological recordings of the cochlear nerve in response to a sound stimulus provide information about the cochlear's ability to encode sound. depending on the stimulus, the fine structure and temporal envelope of the signal will vary, allowing us to determine its characteristics. by phenotyping patients before surgery using subjective and objective audiometric tests, it will be possible to isolate for each patient the moment when the fine structure disappears and when the temporal envelope is effective.

during functional cerebellopontine angle surgery, a spherical electrode is placed on the human cochlear nerve to monitor hearing. once the electrode is in place, clicks and speech signals with and without noise are delivered to analyze the cochlear electrophysiological signal produced. depending on the characteristics recorded, this signal can be used to determine how fine structure and temporal envelope are encoded by the cochlea. prior to surgery, each patient is evaluated by an audiologist to determine quiet and noise thresholds, tone and speech, electrocochleography, distortion testing, tympanometry, abr and psychoacoustic testing.

Eligibility criteria:
inclusion criteria: * the following will be included as hearing-impaired patients: * male or female * over 18 and up to 80 years of age * normal otoscopic examination * scheduled for surgery on the cerebellopontine angle (microvascular decompression) * with sensorineural hearing loss defined by average hearing thresholds between 21 db hl and 40 db hl at 0.5, 1, 2 and 4 khz * affiliated to a social security scheme * having read the information note describing the study and having agreed in writing to participate by signing the informed consent form * will be included as normal-hearing patients: * male or female * over 18 and up to 80 years of age * normal otoscopic examination * scheduled for surgery on the cerebellopontine angle (microvascular decompression) * free of sensorineural hearing loss, defined by average hearing thresholds of less than or equal to 20 db hl in tonal air conduction audiometry, bilaterally on the side of the ear undergoing surgery and on the side not undergoing surgery, at 0.5, 1, 2 and 4 khz * affiliated to a social security scheme * having read the information note describing the study and having agreed in writing to participate by signing the informed consent form exclusion criteria: patients will be excluded from the study if the auditory nerve is not accessible during surgery: * notably because of complete tumor invasion of the cochlear nerve (stage iii and iv neuroma, advanced meningioma) ; * or because of a particular anatomical feature not identified during the preoperative examination, making its exposure for recordings impossible (protrusion of the posterior face of the rock).

Keywords: hearing loss deafness micro vascular decompression otoneurosurgery retrosigmoid approach
can the venus 1000 help clinicians treat patients with severe sepsis or acute heart failure? the cvp trial

Conditions: Severe Sepsis; Acute Heart Failure

Summary: the purpose of this study is to evaluate the impact that the venus 1000 non-invasive cvp system has on the management of emergency department (ed) patients with fluid sensitive conditions.

the ability to non-invasively, accurately, and continuously measure cvp to assess the preload status of ed patients could lead to its inclusion into existing protocols (similar to egdt), or the development of novel protocols for the treatment of patients with fluid sensitive conditions. the majority of other non-invasive measures of preload, such as ultrasound of the inferior vena cava or the passive leg raise technique are not continuous measures and require some type of effort or skill on the part of the clinician. continuous methods of assessing preload include cvp measurement through a central venous catheter, esophageal doppler monitoring, and pulse contour analysis via arterial catheter monitoring, all of which involve invasive procedures. the venus cvp device is non-invasive and has continuous monitoring capabilities. the data acquired from this project will allow us to determine whether emergency physicians will, in practice, utilize the information provided by a non-invasive cvp monitoring device to assist in the management of their patients with severe sepsis or acute hf.

Eligibility criteria:
inclusion criteria: * age 18 years old or greater * english speaking * clinical diagnosis of: 1) severe sepsis, or 2) acute heart failure exclusion criteria: * traumatic injuries * active bleeding * pregnancy * prisoners * central venous catheter placement in the internal jugular or subclavian veins * bilateral external jugular vein catheterizations * concurrent enrollment into an interventional clinical trial that may affect subject treatment